Levonorgestrel-releasing intrauterine system for treatment of heavy menstrual bleeding in adolescents with Glanzmann's Thrombasthenia: illustrated case series.
BMC Womens Health
; 18(1): 45, 2018 02 27.
Article
em En
| MEDLINE
| ID: mdl-29486748
ABSTRACT
BACKGROUND:
Glanzmann's Thrombasthenia (GT) is an inherited genetic disorder caused by defects in the platelet membrane glycoproteins IIb/IIIA, and is associated with heavy menstrual bleeding (HMB). HMB is a common complication in female patients, and many adolescent girls with this disease have issues with HMB beginning at menarche. The available treatment modalities including anti-fibrinolytics, nonsteroidal anti-inflammatory drugs (NSAIDs) and hormonal therapies though are effective, their associated side effects, limited efficacy and the poor compliance is a challenge in management of HMB. Levonorgestrel-releasing intrauterine system (LNG-IUS) has been a potential alternative to overcome this challenge. The use of the LNG-IUS for the management of HMB in adolescents with GT is explored in this case series. CASE PRESENTATION Two adolescents diagnosed with GT and received the LNG-IUS as treatment modality for management of HMB is discussed in this case series.CONCLUSIONS:
For patients with poor compliance to oral hormonal therapies, the use of LNG-IUS is associated with a significant reduction of menstrual blood loss along with improved quality of life. These findings support the use of LNG-IUS to control adolescent GT-related HMB.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Trombastenia
/
Levanogestrel
/
Anticoncepcionais Femininos
/
Dispositivos Intrauterinos Medicados
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article